D. E. Shaw & Co., Inc. Clovis Oncology, Inc. Transaction History

D. E. Shaw & Co., Inc.

$107 Billion
Q3 2024

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$1.05 - $2.85 $47,170 - $128,033	44,924 New	44,924 $53,000
Q2 2022 Aug 15, 2022	SELL	$0.63 - $2.96 $269,958 - $1.27 Million	-428,506 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$1.43 - $3.14 $91,691 - $201,336	64,120 Added 17.6%	428,506 $866,000
Q4 2021 Feb 14, 2022	BUY	$2.7 - $4.76 $946,701 - $1.67 Million	350,630 Added 2548.92%	364,386 $987,000
Q3 2021 Nov 15, 2021	SELL	$4.06 - $5.8 $34,457 - $49,224	-8,487 Reduced 38.16%	13,756 $61,000
Q2 2021 Aug 16, 2021	SELL	$5.02 - $7.05 $171,468 - $240,806	-34,157 Reduced 60.56%	22,243 $129,000
Q1 2021 May 17, 2021	BUY	$4.81 - $10.34 $271,284 - $583,176	56,400 New	56,400 $396,000
Q4 2020 Feb 16, 2021	SELL	$4.13 - $6.41 $60,616 - $94,079	-14,677 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$4.82 - $7.72 $70,743 - $113,306	14,677 New	14,677 $86,000
Q2 2020 Aug 14, 2020	SELL	$5.69 - $9.69 $208,066 - $354,334	-36,567 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$3.77 - $11.0 $1.47 Million - $4.29 Million	-389,964 Reduced 91.43%	36,567 $233,000
Q4 2019 Feb 14, 2020	SELL	$3.0 - $16.43 $4.01 Million - $22 Million	-1,335,983 Reduced 75.8%	426,531 $4.45 Million
Q3 2019 Nov 14, 2019	BUY	$3.93 - $15.35 $3.19 Million - $12.5 Million	812,902 Added 85.6%	1,762,514 $6.93 Million
Q2 2019 Aug 14, 2019	BUY	$12.81 - $25.67 $6.34 Million - $12.7 Million	494,733 Added 108.76%	949,612 $14.1 Million
Q1 2019 May 15, 2019	BUY	$17.66 - $30.28 $7.83 Million - $13.4 Million	443,569 Added 3921.92%	454,879 $11.3 Million
Q4 2018 Feb 14, 2019	SELL	$11.63 - $32.67 $2.62 Million - $7.37 Million	-225,640 Reduced 95.23%	11,310 $203,000
Q3 2018 Nov 14, 2018	BUY	$29.37 - $49.48 $2.01 Million - $3.38 Million	68,392 Added 40.57%	236,950 $6.96 Million
Q2 2018 Aug 14, 2018	SELL	$42.06 - $62.4 $6.33 Million - $9.39 Million	-150,472 Reduced 47.17%	168,558 $7.66 Million
Q1 2018 May 15, 2018	BUY	$50.12 - $67.72 $3.84 Million - $5.19 Million	76,646 Added 31.62%	319,030 $16.8 Million
Q4 2017 Feb 14, 2018	BUY	$57.69 - $84.58 $2.31 Million - $3.38 Million	39,972 Added 19.75%	242,384 $16.5 Million
Q3 2017 Nov 14, 2017	BUY	$67.17 - $84.81 $13.6 Million - $17.2 Million	202,412	202,412 $16.7 Million

Others Institutions Holding CLVS

# of Institutions

Shares Held

166

Call Options Held

Put Options Held

Exane Derivatives

166
Shares

$14
0.0% of portfolio

View Full List

About Clovis Oncology, Inc.

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

More about CLVS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account